{
  "report_rows": [
    {
      "kpi": "Q2 2026 Skyrizi revenue",
      "prediction": "BEAT",
      "answer": "pred ~$5.58B vs. cons $5.49B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Rinvoq revenue",
      "prediction": "BEAT",
      "answer": "pred ~$2.52B vs. cons $2.47B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 total net revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$16.89B vs. cons $16.77B",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Full-year net revenue",
      "prediction": "BETTER",
      "answer": "guide ~$67.8B vs. cons $67.32B (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Full-year adjusted diluted EPS including known IPR&D",
      "prediction": "LOWER",
      "answer": "guide ~$14.13 vs. cons $14.18 (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Skyrizi revenue",
      "prediction": "BETTER",
      "answer": "guide ~$22.0B vs. cons $21.9B (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Rinvoq revenue",
      "prediction": "BETTER",
      "answer": "guide ~$10.4B vs. cons $10.3B (FY 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.2,
  "day5_path": "FADE",
  "day5_rationale": "Skyrizi and Rinvoq beats plus a higher revenue outlook support the initial move, but FY 2026 EPS guidance of ~$14.13 versus $14.18 consensus and roughly $0.46 of expected 2027 Apogee dilution should pull out-period estimates lower, fading part of the day-1 gain.",
  "day5_confidence": "MEDIUM"
}